Ketamine One Appoints Two New Members to Its Medical Advisory Board


VANCOUVER, British Columbia, Jan. 05, 2022 (GLOBE NEWSWIRE) — KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC:KONEF) (Frankfurt: MY0), a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased to announce that Corey Hilmas, MD, PhD has been appointed to the Company's Medical Advisory Board (“MAB“) and will be assuming the role of Interim Chair of the MAB. Additionally, Brigadier General (Ret.) Loree K. Sutton, MD, has also been appointed to the MAB.

Dr. Hilmas currently also serves as the Chief Regulatory Officer of the Company's wholly owned subsidiary, KGK Science Inc. He is a respected scientist, medical doctor, and former federal food regulator in the United States (“US“). After having completed his medical degree and doctorate in toxicology, working as a principal investigator for many years, and serving on behalf of the US government at the Food and Drug Administration (“FDA“), Dr. Hilmas combines his unique medical and scientific skillset with extensive US regulatory training. He served as an New Dietary Ingredients notification reviewer and as a branch chief within the Division of Dietary Supplement Programs at the FDA.

In addition to working on enforcement matters related to supplement labeling, claims, good manufacturing practices and fraud, he also served as an expert witness for the FDA and Department of Justice, resulting in an FDA Award of Merit from former FDA Commissioner Margaret Hamburg. As a recognized regulatory expert with intimate knowledge of the dietary supplement industry, Dr. Hilmas has made significant contributions to building and shaping the regulatory landscape through drafting over 65 comments to multiple US federal and state agencies as well as global food health directorates on topics ranging from soy to supplements and …

Full story available on


Please enter your comment!
Please enter your name here